SCA 2 research July 2022 (NeuroEPO)

:slightly_smiling_face: Interesting news re SCA2 research

NeuroEPO trial in people with SCA2 suggests a small clinical effect

An early-phase clinical trial in people with Spinocerebellar Ataxia Type 2 (SCA2) has tested a potential therapy called human-recombinant erythropoietin (NeuroEPO).

This drug was administered through the nose. The trial found that the 6-month changes in an ataxia score, called the spinocerebellar ataxia functional index, were slightly higher in NeuroEPO group than in the placebo group. However, the NeuroEPO group had a significant decrease in an eye movement measure of reaction time. Overall, these results suggest that NeuroEPO may have a small clinical effect, however further studies are needed on this.